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ABSTRACT
Carbon Nanotube Prosthetic Venous Valve
Ryan Coulton Packer
Department of Mechanical Engineering, BYU
Master of Science
Chronic Venous Insufficiency (CVI) is a disease of the lower limbs that affects millions
of people in the United States. It is categorized by constant venous hypertension, which can lead
to swelling of the legs, pain, skin changes and ulcers. One of the widely known symptoms that
can lead to CVI is varicose veins. The main source of the problem of CVI is incompetent venous
valves. The purpose of venous valves is to direct blood through the veins to the heart and prevent
retrograde flow to the lower limbs. CVI can be caused by leg injury, pregnancy, genetics, age,
and prolonged standing. Current treatments of the disease include compression stocking therapy,
ablation, vein stripping, and valve reconstruction. CVI has become such a problem for patients,
especially those with secondary incompetence in the deep veins, because the current treatments
are used to alleviate the symptoms of the disease but do not treat the source of the problem. One
solution that has great potential is to create an implantable venous valve that could restore function
of the venous system.
In the past many prosthetic venous valves have been made, but none are clinically used
because of problems with biocompatiblility, thrombogenicity caused by high shear rates, and longterm functionality that has been hindered by leaflet stiffening. The purpose of this research was
to create a venous valve that could overcome these difficulties. This was done by designing the
valve out of carbon-infiltrated carbon nanotubes (CI-CNTs). This material has been proven to be
thrombo-resistant, biocompatible due to its non-reactive properties, and durable. The valve was
designed to be initially open and to close with physiological pressures. The shear rate caused by
implantation of the valve was minimized to reduce the likelihood of thrombus formation. FEA and
CFD analysis was performed to verify the valve would function under physiological conditions
and that shear rates would be in the normal range. The final design was tailored for implantation
in the common femoral vein. It had a diameter of 12.7 mm, length of approximately 40 mm, and
thickness of 0.3 mm. With a hydrostatic pressure of 20 mmHg it fully closed with a maximum
stress of 117 MPa, which is below the ultimate strength of CI-CNTs. The CFD analysis demonstrated the valve would cause a maximum shear rate of 225.1 s−1 , which is less than the maximum
shear rate in the body. Currently, this is the lowest shear rate induced by a prosthetic venous
valve. These results demonstrate that a CI-CNT prosthetic venous valve has the potential to be an
effective treatment for CVI.

Keywords: chronic venous insufficiency, venous valves, carbon nanotubes, shear rate
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CHAPTER 1.

1.1

INTRODUCTION

The Problem
Chronic venous disease (CVD) is a very common problem in today’s medical field. Vari-

cose veins affect more than 25 million adults in the United States, and more than 6 million are
affected with advanced venous diseases. Some of the most common symptoms of CVD are telangiectases, reticular veins, and varicose veins. Telangiectasia is a condition where tiny blood vessels
cause threadlike red lines or patterns on the skin [11]. They’re often referred to as spider veins
because of their fine and weblike appearance. Varicose veins occur when veins become dilated and
overfilled with blood. They appear purple or red in color and are often painful [12]. Patients with
varicose veins often have symptoms of aching, burning, pressure, heaviness, or weakness in the
legs after standing or sitting for a long period of time [13]. Reticular veins are similar in appearance to varicose veins but are smaller and usually appear on the back of the leg. They may branch
into telangiectases [13]. Chronic venous insufficiency (CVI) is a condition that affects the venous
system of the lower extremities. CVI is characterized by constant venous hypertension, which
leads to pain, edema, skin changes, and ulcers in the patient. Furthermore, CVI often is associated with more advanced venous disorders, including manifestations such as hyperpigmentation,
venous eczema, lipodermatosclerosis, atrophie blanche, and healed or active ulcers [3]. Hyperpigmentation is a condition in which patches of skin become darker in color than normal skin.
Venous eczema affects the skin of the leg. It becomes itchy, red, swollen, dry, scaly, and flaky.
Venous eczema is usually caused by increased pressure in the legs. This increased pressure can
cause fluid to leak into the surrounding tissue. Venous eczema may occur as a result of the body’s
immune system reacting to the fluid [14]. Lipodermatosclerosis refers to a change in the skin that
can occur due to venous insufficiency. The symptoms include pain, hardening of the skin, moderate redness, increased pigmenation, and small white scarred areas [15]. Atrophie blanche occurs
due to occlusion of small blood vessels in the middle and deep dermis, which prevents normal
1

healing. It is characterized by star-shaped or polyangular, ivory-white depressed atrophic plaques,
prominent red dots within the scar due to enlarged capillary blood vessels, and surrounding hyperpigmentation [16]. Patients not only suffer the physical effects of the disease but also endure
the psychological ailments caused by undesired color changes and bulging of the skin. In severe
cases of CVI involving Deep Vein Thrombosis and Pulmonary Embolism, death can occur [8]. The
risk factors involved in CVI include obesity, pregnancy, family history of varicose veins, age, sex,
previous leg injury, and prolonged standing [3].

1.2

Current Solutions
Current treatments for CVI treat the symptoms of the disease rather than its source. Gen-

erally, doctors will first apply compression therapy, and if needed follow it by laser ablation, sclerotherapy, or stripping. These treatments remove the affected vein from the venous system but do
not attempt to fix the source of the problem. A properly functioning venous system will return
blood to the heart by means of the interaction of a central pump, a pressure gradient, a peripheral
venous pump, and competent venous valves [17]. Often the main source of the problem is the venous valve dysfunction. Their purpose is to direct blood back toward the heart and impede reverse
flow. In the case of CVI, the valves do not close properly and cause hypertension and blood pooling in the lower limbs. When the patients symptoms are serious enough the source of the problem
can be resolved by performing valve reconstruction surgery. Although, the long term success of
this method can be low depending on the type of surgery performed and in certain cases the entire
venous valve may be destroyed, which makes surgery very challenging or even impossible [8, 18].

1.3

Research Motivation
One solution with great potential is to create an implantable prosthetic venous valve that

would restore proper function of the damaged valve. Many attempts have been made to make such
a valve, but none have been successful enough to introduce into the medical field. The main problems with previous prosthetic venous valves have been their competency, patency, thrombogenicity, biocompatability, and incorrect sizing [5]. The purpose of this research is to overcome these
problems by designing a prosthetic valve out of carbon infiltrated carbon nanotubes (CI-CNTs),

2

which have been shown in previous studies to be both thrombogenetic and biocompatible [19–22].
The specific objectives are to design the prosthetic to minimize its potential for thrombus formation, and to function as close as possible to a native venous valve. Thrombus formation will be
minimized by designing the geometry of the valve to reduce the wall shear rates in the vein, which
have been shown to correlate to thrombus growth [9, 23–26]. The valve function will be similar
to a native valve by designing it to be of similar shape and size and to induce leaflet operation
in the same environmental conditions without material or structural failure. With the successful
design of a prosthetic venous valve the source of the problem of CVI will be resolved. A properly
functioning venous valve will direct the blood to the heart and reduce venous hypertension due
to reflux of blood to the lower extremities. This will allow the body to heal more effectively and
function of the venous system will be restored.

1.4

Research Objectives
The objectives of this research are:
1. Design a CI-CNT prosthetic venous valve that performs the same functions as a native

venous valve.
2. Test the conceptual design to ensure its leaflet operation is functional in the environment
of a vein without structural failure.
3. Test the fluid dynamics of the valve to determine its potential for thrombus formation
upon implantation.

1.5

Thesis Outline
The remaining parts of this thesis contain chapters 2 through 5. Chapter 2 discusses the

background of venous anatomy and physiology, its pathology that leads to CVI, current treatments
used by doctors today to alleviate its symptoms, and a history of previous prosthetic venous valve
designs. Chapter 3 relates the structural design and structural analysis of the valve to ensure that
it will operate in the same conditions of the native venous valve without failure. Chapter 4 summarizes the fluid analysis of the valve, which was performed to assure that the implantation of
the valve would minimize wall shear rates and thus thrombus formation. Chapter 5 contains a
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discussion of the results, the concluding remarks of the thesis, and recommendations for future
work.

4

CHAPTER 2.

2.1

BACKGROUND

Venous Anatomy and Physiology
The primary function of the venous system is to return blood to the heart. The physiological

effects of gravity and hydrostatic pressure oppose returning venous flow in the upright position.
To overcome this the body uses a system of valves, an efficient peripheral pump mechanism, and a
small dynamic pressure gradient to overcome the forces of gravity [17]. Blood circulates through
the arteries and veins due to dynamic pressure which originates from the heart. The majority
of the dynamic pressure is dissipated by the arterial system. Normally, the pressure is 12 to 18
mmHg at the venous end of the capillary and decreases toward arterial pressures of 4 to 7 mmHg
[17]. Hydrostatic pressure in the veins is produced by the weight of the blood column below the
right atrium. The pressure is highest in the upright person. During inspiration, diaphragmatic
contraction increases intra-abdominal and lower extremity venous pressure. Ascites and obesity
produce similar increases in pressure even when supine [17].
Venous return from the lower extremity is achieved by the ejection of blood by the lower
extremity muscle pumps with the assistance of competent venous valves. The valves function to
divide the hydrostatic column of blood into segments and prevent retrograde venous flow [17].
Proper functioning of the peripheral venous system depends on the patency of vessels containing
a series of one way valves and muscle pumps. Venous valves are located in the veins to help with
this transportation process. The valves direct the blood flow toward the heart and prevent the blood
from being forced backwards by muscle or mechanical pressures [27].

2.1.1

Venous System
There are three systems of veins in the lower limbs that work together to bring blood back

to the heart [8]. The three systems are the superficial, the deep, and the perforator veins. The
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superficial veins are located above the muscular fascial layer of the limb, or just below the surface
of the skin. They are composed of a network of small veins and several truncal superficial veins,
including the great saphenous vein and small saphenous vein, as well as accesory veins. The deep
veins are located below the muscular fasica. They serve as collecting veins and are the outflow
from the extremity. The deep veins consist of large axial veins, which follow the course of the
major arteries, and intramuscular veins [3]. The perforator veins connect the superficial to the
deep venous system.

2.1.2

Physiology and Anatomy of Venous Valves
The valves within the veins are critical in assuring that blood flows in the correct direction,

especially while in the upright posture [3]. There are two types of vein valves in lower limbs.
The first is ostial valves. These valves are positioned at the entry of a smaller vein branch into a
larger vein, and aid in distribution of blood throughout the leg during leg muscle contractions. The
second type of valves are parietal valves. These valves are generally positioned just proximal to
a venous junction, within the larger vessel of the junction. Parietal valves are the main pressure
bearing valves, and are the more critical valves involved in the CVI and surgical procedures [8].
The venous valves in the lower limbs are generally bi-leaflet, but can have anywhere from
one to five leaflets. The leaflets consist of thin collagen half-moonshaped folds covered by endothelium, which spring from the wall of the vein very close to each other [28]. The valve orifice
is elliptical in nature, with an opening area about 35% of the full luminal area. Leaflets are oriented
such that the longitudinal major axis follows the circumference of the deep fascial cross-section.
Valve leaflets range in thickness from 20-50 microns, and are composed of collagenous fibers covered with two unicellular endothelialized layers [8]. The length of the leaflets can vary greatly,
but as a general rule the vertical length of the leaflets are twice the length of the diameter of the
vein [28]. The valvular sinus is the space between the leaflets and venous wall. The leaflets are
thicker at their bases, where they join the wall of the vein. This thickened attachment of the leaflet
framework is called the agger. The agger acts as a stiffening mechanism to prevent excessive vein
dilation at the point of connection with the valve leaflets. This helps limit vein distention in the
sinus region. The thickness of the vein wall in the sinus region is only 20 to 25% as thick as the
regular vein wall. This permits localized sinus expansion, which is essential for helping the valve
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open and close properly [8]. Venous valves are located throughout the veins of the lower extremity, but their exact location and number can vary for each individual. The most constant valve is
located just below the conjunction of the deep femoral vein. It is found in 90-100% of cases.
For many years doctors and scientists have studied to determine how a venous valve opens
and closes. In the early days of research, the venous valve was believed to close in reaction to reverse flow in the vein or a distally directed pressure gradient. This knowledge was used to diagnosis patients with venous insufficiency. Various methods were used, including changing the patients
position from horizontal to vertical in order to measure the refill time and the valsalva maneuver,
which consisted of compressing the extremity proximal to the segment of interest. Eventually, ultrasound diagnostics were used. Through ultrasound techniques it was determined that retrograde
flow was normal in healthy patients. Interestingly, very little attention was brought on by the finding of reverse flow in veins. Later on, the interest in the mechanism of valve closure resurfaced
with the engineering of artificial valves. It was determined that valve closure required first the cessation of antegrade flow, followed by a brief interval of retrograde flow. Retrograde flow that lasts
less than 0.5 seconds in the upright position is considered healthy, while flow lasting longer than
0.5 seconds is considered pathologic reflux [29]. More recently, experimental and computational
models have shown that the valve geometry and fluid dynamics play a key role in the functioning
of the valve [30].
The valve cycle consists of the opening and closing of the valve and has four phases. The
first phase is the opening phase. In this stage the leaflets move from the closed position toward the
sinus wall. On average this stage lasts for 0.3 seconds in the horizontal position [30]. Next is the
equilibrium phase. In this phase the leading edges of the leaflet remain suspended in the flowing
stream and undergo self-excited oscillation, which resembles a waving flag. After that, the closing
phase begins. As the axial velocity of blood passing through the valve increases, the pressure on the
luminal side of the leaflet decreases. The leaflets then start moving toward the center of the vein.
With rising pressures on the mural side and falling pressures on the luminal side of the cusps, valve
closure is favored [30]. The leaflets move synchronously toward the center of the vein. This action
take around 0.4 seconds for a patient at rest and shorter when foot movements are performed. The
final step of the process is the closed phase, in which the leaflets remain closed [1, 30].
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The hemodynamics is also important in the functioning of the valve. Lurie et al. were
able to observe the fluid dynamics involved in the opening and closing of the valves by use of an
ultrasound [30]. They observed that when the valve was opened it never touched the vein wall, but
was opened a distance from the wall. It was determined that one crucial part of the flow dynamics
was the sinus. While the valve leaflets were in their open position, the flow in the sinus was
directed proximally. Eventually, flow separation occurred at the leading edge of the leaflets (See
Fig. 2.1). The flow split into two streams. The larger stream, located at the center of the vein,
was directed proximally through the vein. The smaller part of the flow, at the point of attachment,
turned into the sinus. It then formed a vortex along the sinus wall and the mural side of the valve
leaflets and exited by rejoining the main stream in the vein. This vortex lasts for the equilibrium
and closing phases of the valve cycle. The velocity of the blood also changes as it passes through
the valve. When the valve is maximally opened, the leaflets make a funnel like narrowing. This
narrowing causes the flow to accelerate, resulting in a proximally directed flow jet. The accelerated
flow impacts a layer of slower moving blood proximal to the valve. This impact causes the flow to
reflect at the mural parts of the stream. These reflected streams reinforce the mural part of the sinus
vortex, while the central part of the stream accelerates under the axial pressure of the jet [1, 30].
As vortical flow continues, it applies pressure to the mural surface of the valve leaflets. When the
pressure on the mural side of the leaflet and the pressure on the luminal side are in equilibrium,
the valve remains open. This dynamic equilibrium is sustained by equilibrium in velocity of the
two streams. Changes in any of these streams can lead to closure of the valve [1, 30]. Self-excited
oscillations of the leading edges of the leaflets that occur during this equilibrium phase make this
balance unstable and very sensitive to small changes in flow [30].
These flow characteristics inside the sinus are essential for keeping the leaflets away from
the vein wall and for valve closure. The vortex flow limits the amount of stagnant blood in the sinus, which prevents coagulation. Experiments have shown that when this flushing motion doesn’t
happen regularly, the oxygen content of the blood in the sinus drops. This happens when blood
flow is continuous. Avascularity of the valve leaflets can lead to ischemic damage. This means
that if continuous flow occurs for a prolonged time period, followed by reperfusion of valve pockets, valve thrombi may be likely to form. When venous valves close in reaction to increasing
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Figure 2.1: This picture represents the flow dynamics that occur in the vein near the venous valve
(image from [1]) .

flow velocity, they stop continuous flow converting it into pulsatile flow, which provides adequate
oxygenation of valve pockets and prevents formation of thrombi [30].

2.1.3

Role of Muscle Pumps
The muscle pumps of the body also play an important role in returning blood to the heart.

As the muscles contract they eject blood into the veins of the lower extremity. The main muscle
pumps are the foot, thigh, and calf muscles. The calf muscle pump is the most important because it
is the most efficient. It has the largest capacitance and can produce pressures up to 200 mmHg. The
calf muscle pump ejects 40-60% of the venous volume in one muscle contraction [17]. Different
venous valves open at different times throughout the calf pump cycle [8, 31]. As the calf muscles
contract the deep vein valves open and valves distal to the muscle contraction close. This sequence
ensures that blood is directed toward the heart and to the deep veins [8, 32].

2.2

Pathophysiology of CVI
CVI can be caused by wide range of risk factors. Some factors have to do with the lifestyle

of the patient, like obesity and prolonged standing. Other factors that increase the contraction
of the disease are the age and sex of the patient, if they have a family history of varicose veins,
the frequency of pregnancy, and their history of phlebitis or a previous leg injury [3]. Scott et
al. did a study to determine the influence of various risk factors on varicose veins and CVI [33].
They wanted to determine if certain diseases increased the risk for CVI and varicose veins or if it
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was brought on simply by older age. Ninety-three patients with venous ulcers, 129 patients with
varicose veins, and 113 general population control patients from two hospitals were interviewed.
Univariate and multivariate analyses were used to compare the groups. Age-adjusted relationships
for CVI include male sex and obesity. Histories of serious leg injury or phlebitis were important
associations resulting in a 2.4-fold and 25.7-fold increase in risk for CVI, respectively. After
adjusting for age, subjects with varicose veins tend to be younger and female. Those with a history
of phlebitis had a 6.3-fold increased risk for varicose veins. The greater risk factor for varicose
veins was a family history associated with the disease, which accounted for 85% of the patients
with varicose veins. The analysis suggested that the greater likelihood for the patients with CVI
to have hypertension, heart disease, or their increased frequency of child bearing, was a result of
the greater age of the patients with CVI. Diabetes was the only risk factor that continued to show
an association with CVI; although, it was only of borderline statistical significance. Results of
the study showed that CVI may be the result of a more local phenomenon rather than a systemic
ailment [33].
Venous pathology occurs when venous pressure is increased and return of blood is impaired through several mechanisms. This can happen from valvular incompetence of axial deep
or superficial veins, perforator veins, venous tributaries, or venous obstruction, or a combination
of these mechanisms [3]. The main cause of CVI is that the venous valves of the patients become
incompetent and can not seal properly, which results in venous reflux and in distal venous hypertension (See Fig. 2.2). These factors are worsened by muscle pump dysfunction. Untreated venous
hypertension may result in dermal changes with hyperpigmentation, subcutaneous tissue fibrosis,
and eventual ulceration [3].

2.2.1

Valvular Incompetence
There are two types of valvular incompetence, primary and secondary. Primary valve in-

competence involves the aging process and arises as the structural composition of the vein changes.
In an aging vein wall, the intima thickens and elastin fibers and muscle layers become disoriented
and disorganized. Elastic lamina within the intima becomes more fragmented and irregular. The
reduction of elastic lamina in veins makes it more vulnerable to high pressure distention. As veins
distend, the valves also distend to the point where the leaflets no longer meet to seal properly [8].
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Figure 2.2: Comparison of varicose veins to normal functioning veins. The improper sealing of
valves allows blood to reflux back into the lower extremities (image from [2]) .

Secondary valve incompetence develops after deep venous thrombosis and involves valves of the
deep venous system [6]. This incompetence is a result of destroyed vein valves. The leaflets become adherent, folding over, and being absorbed into the vein wall. Valve damage often occurs due
to thrombus formation. Poor sealing of valves leads to regurgitation and turbulence of blood flow,
while other areas of the vein experience stagnant flow; this increases the possibility of thrombus
formation. Thrombus growth can lead to the dysfunction of the vein valve. The absence of one
vein valve results in additional pressure applied on the next valve distal to the missing valve, and
the process of vein distention and valve destruction propagates down the lower limbs [8].
Incompetence in the lower limbs may be spread throughout the system or be isolated into
one part of the leg. In 1995 Labropoulos et al. did a study on the frequency of incompetence in the
lower limbs. A group of 94 patients, with 112 ulcerated limbs, was studied. Incompetence in more
than one system of the limbs was seen in 64% of cases, while single system incompetence was
observed in 32% of cases. Isolated deep venous incompetence was only seen in 6% of the patients
and in 4% there was no venous reflux. Isolated superficial vein incompetence occurred in 23% of
patients. 32% of reflux was confined to the below knee segment of the LSV and tribuitaries. In
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the above knee segment, 42% of patients had an incidence of LSV reflux [34]. This study showed
that majority of reflux happens above the knee segment, despite the fact that above knee segment
reflux does not contribute as highly to ulceration.
Another study performed by Moore et al. was done to determine the relationship between
the location of venous incompetence and the severity of the clinical symptoms. The records of
122 patients who underwent Doppler evaluation were reviewed. There were 35 patients with perimalleolar ulcers, 113 with stasis pigmentation, 26 with swelling, and 70 with no apparent symptoms [35]. The study found that proximal deep venous incompetence was not strongly correlated
with disease severity, but distal and superficial venous incompetence were. The relative frequency
of isolated proximal incompetence appeared to diminish with increasing disease severity. On the
other hand, the frequency of distal incompetence, with or without associated proximal venous incompetence, increased. Superficial venous incompetence was much more closely associated with
distal deep venous incompetence than with proximal deep venous incompetence. The high rate
of superficial incompetence was thought to be a majority, if not in all cases of a secondary nature
and represented collateral channels developed to compensate for deep venous disease. Johnson et
al., in a long-term follow-up of 12 limbs with isolated deep venous valve repair, have documented
the significant influence of superficial vein incompetence and have emphasized that both deep and
superficial vein incompetence must be addressed to achieve satisfactory control of symptoms [36].
These studies show that often chronic venous disease is a multi-system problem and may require
reconstruction in several locations.

2.3

Current Treatments
The majority of current treatments for chronic venous insufficiency treat the symptoms of

the disease rather than the source (See Fig. 2.3). First the patient is given conservative treatments,
such as compressive therapy. In this type of therapy a compressive stocking is worn on the leg.
The purpose of this treatment is to provide graded external compression to the leg and oppose the
hydrostatic forces of venous hypertension. If this therapy produces positive results the treatment is
continued. On the other hand, if the patients response is unsatisfactory or the disease is categorized
as advanced, non-invasive testing is performed. Non-invasive tests may include Duplex ultrasound
scanning or air plethysmography. After performing the non-invasive tests the doctor may find that
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the vein has non-acute obstruction, reflux, or that the muscle pump of the lower limb is not working
properly.
If the muscle pump is not working properly the surgeon will recommend a calf exercise
program. In the case of non-acute obstruction, something is blocking or disrupting the flow of
blood in the vein. Obstruction of the deep veins decreases the outflow of blood. Obstruction may
be caused by chronic deep vein thrombosis, venous stenosis, or extrinsic compression. After futher
tests, such as venography, the surgeon most often performs a venous stenting on the vein.
When reflux is the problem of the disease, the doctor will advise a treatement depending
on the location of the reflux. Common treatments for the superficial system are ablation, foam
sclerotherapy, or stripping. Ablation is when thermal energy in the form of radiofreqency or a
laser is used to close incompetent veins. Complications can arise with this procedure, which may
include deep venous thrombosis and pulmonary embolism. Sclerotherapy is a procedure involving
the injection of a solution into the vein. The solution then irritates the lining of the blood vessel and
causes the blood to clot. With time, the vessel turns into scar tissure and fades away. This method
completely elimates the vein with reflux, but complications can occur, such as hyperpigmentation
of the surrounding skin from hemosiderin degradation. Stripping involves removing the vein from
the body. Similar complications can occur, including deep vein thrombosis, pulmonary embolism,
nerve damage, and post operative bleeding. Another problem present in these procedures is the
tendency for varicose veins and other symptoms to reoccur. In some cases neovascularization,
or new blood vessel formation, can occur in the granulation tissue along the track of previously
stripped or ligated veins. Neovascularization has been reported to account for 8 to 60% of recurrent
varicose veins [37–42], and is the most common cause of recurrence [37, 43–48].
Perforator vein reflux is treated by ablation, foam sclerotherapy, or subfasical endoscopic
perforator surgery (SEPS). SEPS involves ligation and clipping of abnormal perforator veins. It
occludes the vein with a surgical clip. Normal techniques can be harder in treating perforator
reflux because of pre-existing tissue damage. SEPS can help avert this difficulty by performing the
surgery from a site that is not directly penetrating the affected skin area [3].
In the case of deep vein reflux, the veins cannot be removed because they are the main
pathway for blood to return to the heart. Further testing is done using venography in order to
better access the state of the valve. If the conditions are appropriate after verifying the valve’s
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condition then valve reconstruction is performed. For valve reconstruction there are a few commonly used techniques, including valvuloplasties, valve transpositions, and valve transplantations.
The technique used depends on the type of valve incompetence. For primary valve incompetence
valvuloplasties are performed. Primary incompetence results in widening of the valve commissural angle and elongation of the valve leaflets. This causes the valve leaflets to not seal properly.
A valvuloplasty is used to correct this problem. Valvuloplasty involves the placement of several
sutures where the valve leaflets join the vein wall, to help restructure the valve leaflets to their
original anatomy [8].
Secondary incompetence is not as easily treated with surgery. In these cases the valves are
usually severely damaged due to deep vein thrombosis. Many times the valves are beyond reconstruction repair and must be replaced. The procedures used in these cases are valve transplantation
and valve transposition. In valve transposition the surgeon cuts the main vein in the incompetent
vein and sutures it into place below one of the other veins in the leg that has a working valve. In
some patients there may not be such a valve present. There is also a concern that overtime the extra
work the working valve must do could cause the vein to dilate and the valve to fail [49]. Valve
relocation is used when vein transposition is not possible. It involves taking a segment of the vein
of a less essential, similar sized, working valve and suturing it into place where the dysfunctional
valve is. This is done many times with the axillary vein valve, since it is similar in size with the
femoral vein. In this particular procedure a segment of vein with a good functioning valve is taken
from the arm veins through a small incision in the armpit. This valve segment is then placed into
the lower leg incompetent vein system by suturing it to both ends of the cut deep leg vein [49]. In
a study by Raju et al., despite careful attention to detail, 16% of axillary vein transfers were still
mildly leaky after surgery [50].
Other less often used procedures used for deep venous reflux are prosthetic sleeve in situ,
transcommissural repair with optional angioscopic control, denovo valve reconstruction, and venoplastic procedures. Prosthetic sleeve in situ is used when intially refluxive valves become competent during surgery due to venoconstriction. A Dacron or polytetrafluoroethylene sleeve may be
fitted around the valve in such cases to maintain the valve annulus at a slightly constricted state to
assure competency. Transcommissural repair is an external procedure. This treatment uses transluminal sutures to close the comissural valve angle while simultaneously tightening the valve cusp.
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This repair is preferred over external valvuloplasty, which closes the valve angle by transmural
sutures without tightening the valve cusps. Denovo valve reconstruction is performed on patients
that have a completely destroyed postthrombotic valve. Usually axillary vein transfer remains the
treatment of choice. However, in some patients the axillary vein valve may be incompetent. In
these cases the valve can be fashioned out of harvested saphenous vein. Venoplastic procedures
pull up and tighten the valve cusps without direct placement of sutures on the cusps themselves.
The valve sinuses are also enlarged and deepened. This procedure is a good technique when intraluminal valve exposure for internal valvuloplasty is difficult due to the small vein size or when the
commissural valve angle is extremely wide [50].
Overall, valvuloplasty is the most frequent procedure used for primary deep reflux. Valvuloplasty acheives a good result in 70% of cases in terms of clinical outcome defined as a freedom of
ulcer recurrence and reduction of pain, along with valve competence and hemodynamic improvement over a follow-up period of more than 5 years [18]. External transmural valvuloplasty does
not seem to be as reliable as internal valvuloplasty in terms of its long-term valve competence or
ulcer free survival. A good result of only 50% is obtained in transposition and transplantation, with
a poor correlation between clinical and hemodynamic outcome [18]. Better results are obtained in
the treatment of primary reflux compared with secondary reflux.

2.3.1

Venous Valve Prostheses
Current management of chronic deep venous incompetence is limited to procedures that

manage symptoms rather than fixing the source of the problem. Prosthetic valve implantation
is one alternative, which may restore all or part of the function of the native venous valve, thus
fixing the source of the problem of the disease. Although many prosthetic valve designs have been
made in the last few decades, long-term durability and thrombosis remain as major difficulties [51].
Prosthetic venous valves can be categorized into two groups, bioprosthetic, and mechanical valves.
Bioprosthetic valves are valves made out of material of another animal or humans. Mechanical
valves are created from man-made materials.
One of the earliest bioprosthetic designs was made in 1965. These allograft valves were
implanted into the femoral veins of 14 dogs. In the one month study 7% had patency [6, 52].
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Figure 2.3: Diagram showing the current treatments for patients depending on their symptoms
(image from [3]).

In another study, a gluteraldehyde fixed human umbilical vein and liquid pellethane bicuspid valve were fitted over a metallic mandrel. This valve had an opening pressure of 4.5 mmHg.
After 47 days of fatigue-cycles at 120/80 mmHg pressures at 60 bpm the valve showed no signs
of material weakening. The valves were supported in place by quarter inch stainless steel cylinders which were surrounded by the vein to prevent blood contact. The valves were implanted into
jugular veins of 10 dogs. All the implants were clotted within 8 days [5, 6, 53].
A decellularlized allograft venous valve was made and implanted into the jugular vein of
sheep. All failed due to thrombosis by week 6 [6, 54]. The same valve design was repopulated
with donor smooth muscle and endothelial cells and then implanted into 12 sheep. At 12 weeks,
9 out of 12 of the valves were patent and competent without anticoagulation. 2 of the valves were
rigid due to neointimal growth and one was thrombosed [6, 54].
Kusher et al. encased 8mm Symphony stents inside external jugular vein segments containing valves harvested from dogs. They compared their performance to end-to-end anastomosis
grafts in seven dogs [55]. Seven valves were implanted. In one dog both grafts occluded in less
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than 2 weeks. The remaining valves and grafts were still patent after 120 days. Minimal to moderate stenosis was present at the suture lines which raised concerns that thrombosis may be caused
from the sutures themselves [5].
A bioprosthetic valve was made that consisted of a segment of a glutaraldehyde-fixed,
bovine external jugular vein valve. It was sutured inside a self expanding nitinol stent (See
Fig. 2.4). It was implanted into the iliac vein of 11 pigs using 12-24 French catheters. In the
three short term animals, the valves were competent and patent at 2 weeks [4, 6]. Five valves were
competent at implantation. Of the four survival procedures, one pig died by one week, presumed
to be from exsanguination, and had its leaflets entrapped by postmortem thrombus. The other three
were sacrificed at 1-2 weeks and had valves that were still patent and competent. All four valves
had pronounced inflammatory foreign body reactions [5].

Figure 2.4: Picture of the venous bioprosthesis created by Gomez-Jorge et al. (A) Segment of
bovine jugular vein with leaflets. (B) Vein segments trimmed and sutured to a nitinol stent. (C)
Bioprosthesis compressed and loaded within an 18-Fr introducer (image from [4]).

Implantation of a similar glutaraldehyde-preserved bovine vein with a native vein valve
took place in the iliac vein of pigs (See Fig. 2.5). In vitro testing found valve reflux under a 287
mmHg pressure head to be 120 mL/min in valves made from fresh specimens and 40 L/min in
fixed tissue valves. The pressure drop across the valve was 2.9 mmHg with a flow rate of 1200
mL/min, resulting in a combined resistance of 322 mmHg*min/L for the flow system and the
valve [5]. These valves were sutured inside a memory-coded nitinol frame and were deployed in
18 iliac veins in 10 young pigs. In group 1, the group that was given a vitamin K antagonist, 7 stent
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valves were patent and 3 competent at 2 weeks. Eventually all the pigs had bleeding complications
and were sacrificed at 2 weeks. One valve migrated and thrombosed. Thrombosis occurred in 5
out of 10 valves in group II, the group that was given aspirin and clopidogrel, at 4 weeks followup [6, 56]. 5 of the valves were patent and 3 were competent. The valve was also implanted into
5 human subjects. One valve remained patent and competent at 16 months, the remaining four
valves occluded. One valve migrated into the pulmonary artery. Ultimately this valve was deemed
unfit for further use in venous implantation [5, 6].

Figure 2.5: Glutaraldehyde preserved bicuspid bovine valve attached to the self expanding stent
(image from [5]).

Three bioprosthetic valves were created that consisted of a small leaflet of small intestinal
submucosa (SIS) attached to different types of square stent frames. SIS is a relatively acellular,
non-immunogenic, biodegradable, collagen based biomaterial derived from the submucosal layer
of porcine small intestine. The SIS material is a material that provides a temporary scaffold for
cellular colonization. In the first prototype (BVV1), the cusp consisted of SIS and the native vein
wall was lined with extracellular cells (See Fig. 2.6). The valve was implanted using a 11 French
catheter into the jugular vein of 12 sheep. 24 out of 25 valves were patent, only 1 occluded at 1
month due to tilting of the valve. 22 of the valves had limited cusp flexibility due to the leaflet
thickening [6, 57]. These results indicated that BVV1 prevented occlusion of the valves but did
not prevent the intimal hyperplasia of implanted SIS leaflets. On 3 and 6-month specimens, the
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completely remodeled SIS matrix was covered with neointima consisting of extracellular cells, and
fibroblasts with collagen deposits that caused leaflet thickening [57].
The second version of the valve (BVV2) was made to improve the valves position during
placement and ensure its centering in the vein without tilting. It was made with nitinol tubing [58].
A second square stent without barbs was added to the midpoint of the original valve (See Fig. 2.6).
28 of these new valves were placed in the jugular vein of 14 sheep. At 6 weeks follow-up, 26
valves remained functional [6]. Only two oversized valves were incompetent and exhibited reflux.
A third version of the valve (BVV3), was designed to prevent contact of free leaflet portions
of the valve with the venous wall and ensure continued leaflet coaptation (See Fig. 2.6). The round
geometry of BVV3 allowed the leaflets to coapt and improved blood flow in the larger pockets of
the valve, which prevented potential thrombus formation. All the valves remained functional and
stable on a 5 week follow-up study [6,59]. BVV3 valves were later implanted into 15 patients with
a 12 French catheter. One valve was incompetent at implantation. Four valves occluded, 3 in less
than 2 weeks and one at 7 months. At 3 months only 2 valves remained competent. At 12 months
none of the valves had migrated and none were competent [5]. The bioprosthetic venous valves
made by Pavcnik et al. functioned well in the short term, but in the long term the scaffolding nature
of the SIS caused the leaflets to thicken, become rigid, and the valves became incompetent [6].
Extensive research has also been done on mechanical venous valves. In 1993, a prosthetic
venous valve was made that consisted of a thin polyether urethane membrane inside a single body
z-stent (See Fig. 2.7). It worked well for 1 week, however partial thrombosis appeared inside the
valve [6].
A platinum or pyrite carbon-covered titanium bileaflet valve was implanted into canine
femoral veins. A bileaflet design with centrally hinged hemidiscs and a ring containing a central
circumferential groove to allow anchoring to the vein wall was implemented (See Fig. 2.8). The
valves were patent and competent at 3 months, but by 2 years extensive neointimal overgrowth
resulted in valve failure [6, 60].
Researchers form the University of Akron developed three generations of prosthetic venous
valves [5, 7, 61–63]. The valves were tested by applying a forward flow rate of 1600 mL/min,
which corresponds to flexing the ankle while standing. A back pressure of approximately 40
mmHg was applied to the valves with a column of solution 55 cm above the devices [5]. The first
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Figure 2.6: Three types of bioprosthetic venous valves (BVV): (A) frontal view of the original
design of the square stent based BVV1; (B) side view of the BVV1; (C) side view of the BVV2;
(D) side view of the BVV3 (images from [6]).

generation design underwent seven iterations which focused on improving leaflet closure while
preventing unwanted leaflet buckling. Experimental testing for the second and third generation
valves used a 3.45% dextran solution, which simulated the characteristics of human blood. The
second generation design consisted of a rigid frame with polyether urethane flexible leaflets that
were naturally open (See Fig. 2.10). The parameters of interest for the second and third generation
valves were the resistance the device imposed on antegrade flow and the device’s ability to prevent
retrograde flow. The valve had a mean reflux volume of 5.83 mL over approximately 4 seconds,
which corresponds to an average reflux flow rate of 87.45 mL/min, and increased the outflow
resistance by 1.35-1.58 mmHg*min/L [61]. A computation fluid dynamics (CFD) simulation of
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Figure 2.7: Monocusp Z-stent valve (image from [6]).

Figure 2.8: Platinum titanium bileaflet valve (image from [5]).

blood flowing through the valve inside a 12.57 mm vein with an inlet flow rate of 700 mL/min
resulted in a maximum shear rate of approximately 7600 s−1 [63]. A third generation valve was
developed because of the concern of high residence time of the fluid behind the leaflets in the
CFD simulation. The design had bowl shaped leaflets which were naturally closed and opened by
moving toward the center of the vein as flow moved forward (See Fig. 2.11). This valve had a mean
reflux volume of 14.25 mL/min, and increased the outflow resistance by 1.15-4.66 mmHg*min/L
[7].
Sathe created a prosthetic venous valve made out of poly(vinyl-alcohol) (PVA) cryogel (See
Fig. 2.12). In the past prosthetic venous valves have faced problems due to thrombus formation and
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Figure 2.9: The first generation prosthetic venous valve from the University of Akron (image
from [7]).

Figure 2.10: The second generation prosthetic venous valve from the University of Akron (image
from [7]).

valves leaking when a back pressure has been applied. The goal of Sathe’s valve was to overcome
these problems by designing a valve that was thrombo-resistant, that could withstand 300 mmHg
of back pressure with less than 1 mL/min of leakage, that would open with a pressure gradient less
than 5 mmHg, and meet these criteria after 500,000 cycles of testing [8]. In his first design, Sathe
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Figure 2.11: The third generation prosthetic venous valve design form the University of Akron
(image from [7]).

made a valve with pre-opened leaflets. The valve was exposed to a pressure of 74 mmHg. The valve
design did not seal against reflux. It had a leak rate of 1 mL/sec. In his second design, the valve
had pre-closed leaflets. The valve leaked profusely around the circumference of the valve when it
was exposed to pressures above 20 mmHg. In his third design, the valve was made of pre-closed
leaflets and a flared inlet and outlet. The valve demonstrated competency at physiologic pressures
between 35 and 50 mmHg. It opened at a pressure of 5.9 ± 0.9 mmHg. At pressures below 230
mmHg, the valve had a leak-rate less than 1 mL/min. In the final design the valve thickness was
decreased at the inlet and the outlet to minimize the profile of the valve in the vein and to allow
the valve ends to conform more easily to the tortuous venous anatomy. The final design had a
reflux flow rate less than 0.3 mL/min under an applied back pressure up to 300 mmHg before and
after 500,000 cycles. The valve increased the outflow resistance by 324.6 mmHg*min/L [5, 8].
A CFD simulation of the open configuration of this valve in a 10 mm vein with an average inlet
flow velocity of 0.27 m/s, which is equivalent to an inlet flow rate of approximately 1300 mL/min,
resulted in shear rates greater than 10,000 s−1 [5, 9]. The valve occluded in an in vitro porcine
blood flow loop in less than 20 minutes with a 470 mL/min forward flow induced by a roller pump.
Two valves were implanted into a sheep and were not patent when examined at 5 weeks. It was
hypothesized that thrombus had formed in response to elevated shear rates from the valves narrow
orifice [5].
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Figure 2.12: The prosthetic venous valve created by Sathe (image from [8]).

Midha designed a naturally open venous valve that had lower shear rates than previous
valves. He made his valve by recognizing the three potential causes for valve failure by thrombosis, biomaterial-induced thrombosis, very high shear stress platelet activation and aggregation,
and very low shear stress coagulation [9, 23, 24]. Shear rates as high as 5000 s−1 have been shown
to exist in the body [25]. Shear rates under 46 s−1 have been shown to cause thrombosis through
coagulation [26]. After performing a CFD Analysis, Midha hypothesized that Sathe’s valve occluded because of the high shear rates it caused in the vein. This behavior was due to the valve’s
small opening area, which was 3.5% of the original vein area. Midha designed his valve to have a
larger opening area and thus decrease the shear rate caused by the valve. The orifice of the valve
was made into a lemon shape to allow full closure of the valve leaflets. The valve was tested in a
very similar way to Sathe’s valve by cycling the valve through 500,000 cycles of testing. It had a
mean reflux flow rate of 30.8 mL/min before and 41.1 mL/min after 500,000 cycles of testing, both
with a applied back pressure of 75 mmHg. Small gaps remained after leaflet closure at the corners
where the two leaflets joined which allowed this amount of reflux. The valve increased the outflow
resistance by 7.3 mmHg*min/L. A CFD simulation of this valve in a 10 mm vein with an average
inlet flow velocity of 0.27 m/s, corresponding to an inlet flow rate of approximately 1300 mL/min,
predicted shear rates up to 3,000 s−1 . Shear rates below 46 s−1 existed primarily at the bottom of
the sinus region behind the leaflets [9]. The valve did not occlude in an in vitro porcine blood flow
loop after 3 hours with a 470 mL/min forward flow induced by a roller pump. Four of the valves
were then implanted into 2 sheep. All implanted valves remained patent through the first week
with no signs of narrowing or collateral flow. At week 2, each sheep had 1 occluded valve and 1
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patent valve. Only one valve remained patent at week 6. It was hypothesized that thrombus had
formed due to elevated shear rates caused by radial buckling of the valves. The base of the valve
had a tendency to radially buckle because of the ovular shape of the shoulder [5, 9].

Figure 2.13: The prosthetic venous valve created by Midha (image from [9]).

Tanner manufactured a naturally open valve made of PVA. The main challenges he designed the valve to overcome were thrombogenicity, biocompatibility, and incorrect sizing. PVA
was used because it passed biocompatibility tests by ISO and USFDA [64]. It has also been shown
to be less thrombogenic than Dacron when profused with porcine blood [65, 66]. The design criteria was to have the valve’s reflux flow rate below the minimum competent reflux flow rate at
physiologic pressures, after 500,000 cycles of fatigue testing. The time average reflux flow rate
for incompetent CFV, femoral, and popliteal veins is 3-3357 mL/min [67]. Retrograde pressure
can range from 30-100 mmHg and can increase an additional 30 mmHg with the valsalva maneuver [17, 68–70]. To design for this and have a factor of safety, Tanner’s criteria was that the valve
have a reflux flow rate less than 3 mL/min with a back pressure ranging from 30-160 mmHg. The
venous valve was also designed to minimize outflow resistance and shear rates. To accomplish
this the valve was made with an elliptical orifice at the top of the valve’s base, which linearly
transitioned into a lemon shaped orifice by the time it reached half the height of the leaflets. This
linear transition helped keep the shear rate low while decreasing the risk of prolapse. Slits were
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also made at the top of the leaflets at the corners of the orifice in order to improve sealing (See
Fig. 2.14). This enabled the leaflets to seal better by eliminating any gaps that would otherwise
exist at the corners of the leaflets during closure. After experimental testing similar to Sathe’s
valve the average reflux flow rate was 0.44 ± 0.20 mL/min and 0.30 ± 0.27 mL/min under 30 and
160 mmHg pressure heads, respectively. The average resistance added by the valves was 2.3 ± 1.0
mmHg*min/L. After performing CFD on the valve, the maximum shear rate was 2300 s−1 . Shear
rates below 50 s−1 were present behind the leaflets. In the fatigue test the valve was not competent
when it operated at 6 Hz. It was able to be competent when the frequency of operation was cut in
half [5].

Figure 2.14: The prosthetic venous valve created by Tanner before (left) and after (right) 500,000
cycles of fatigue testing (image from [5]).
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CHAPTER 3.

3.1

PROSTHETIC VENOUS VALVE STRUCTURAL DESIGN

Design Criteria
The objectives of this research are to create a prosthetic venous valve to help in the treat-

ment of secondary venous incompetence for patients with CVI. In the past many vein valve designs
have been made and great improvements have been accomplished in reducing valve reflux rates,
shear rates, and outflow resistance, but many difficulties are still present. The main problems that
have prevented the advancement of prosthetic venous valves are their biocompatibility, thrombogenicity, correct sizing, and durability. Several key features are needed to develop a prosthetic
venous valve design that can overcome these challenges and have similar characteristics to a native
venous valve (See Table 3.1).

3.1.1

Functional Requirements
One important feature is how easily the leaflets of the prosthetic open. This is essential

since dynamic pressures in the vein are low and a valve that can’t open with physiologic pressures is
nothing more than an obstruction. The leaflets of a native venous valve open with less than 5 mmHg
[8]. Another important feature is the closing of the valve. Valve closure ensures venous flow is
directed towards the heart and does not flow back into the lower extremities. A retrograde pressure
as low as 22 mmHg, caused by hydrostatic pressure, closes the leaflets [17]. The mechanism
should also be similar in shape and size to the native valve to not alter the hemodynamics of the
vein and to replicate its function. It is important that the length of the valve is long enough to
provide stability, but not too long that it interferes with the fluid dynamics of the vein. The length
of the prosthetic valve should be 1-2 times greater than the diameter of the valve. In a natural
bi-leaflet vein valve, the leaflet length is usually twice the diameter of the vein [8, 27]. Thus, the
length of the prosthetic leaflets should be close to 2 times greater than the vein diameter.
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3.1.2

Thrombogenicity
The vein valve also must not promote thrombus formation. In the past many prosthetic

venous valves have done well in experimental tests, but they ultimately failed and coagulated once
they were put in blood and animal experimentation. Thrombus formation has been shown to occur
in regions of stagnant blood [71]. Elevated shear rates can also increase the risk of thrombosis.
The maximum thrombus growth rate in human blood occurs at a wall shear rate of approximately
10,000 s−1 [72, 73]. Physiologic shear rates are generally considered below 3,500 s−1 [74]. To
avoid blood coagulation and major changes to the vein hemodynamics the prosthetic venous valve
must be designed as thin as possible and have a shear rate below 3,500 s−1 . The material that
the prosthetic valve is made of should have low thrombogenicity. Currently, there are no tests to
quantify a material’s thrombogenicity. A comparison to an FDA approved blood compatible device
can be useful.

3.1.3

Biocompatibility
The final design criteria is that the prosthetic be made out of a material that is biocompatible

and can retain its function in the long term. A material is biocompatible if it does not cause
inflammation, or a foreign body reaction when placed in the blood stream. In the past, several
devices have been biocompatible, but with time proteins and cells from the body have attached to
the device’s leaflets. This caused the leaflets to thicken and the valves became dysfunctional. An
effective prosthetic venous valve must be biocompatible and not lose its function with time. This
can be attained by using a material that is resistant to cell attachment.

3.1.4

Material Selection
Prosthetic venous valves have been made out of a wide variety of different materials. These

materials have ranged from animal specimens to titanium to blood-compatible polymers. Many of
these devices have not been successful in the short term because the materials they were composed
of were not entirely blood-compatible. Those that were successful in the short-term, failed in the
long-term because of neointimal hyperplasia or durability problems, such as radial buckling. A
prosthetic venous valve composed of CI-CNTs has not yet been attempted. Carbon nanotubes
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Table 3.1: Design Criteria
Design Parameter
Leaflet Operation

Length of valve
Length of leaflets
Thrombogenicity

Biocompatibility

Specification
Naturally closed leaflets must open with 5 mmHg and naturally
open leaflets must close with a hydrostatic pressure of 20 mmHg
without exceeding the ultimate strength of the material
1-2 times the diameter of the vein
2 times the diameter of the vein
Wall shear rates must be below 3500 s−1 , the valve’s thickness
and regions of stagnant blood flow must be minimized, and the
material must not promote thrombus formation
Material should not cause a foreign body reaction and be resistant
to cell buildup on the valve’s leaflets

could be a material that helps overcome these problems because it has been proven to be thromboresistant compared to other materials (see Fig. 3.1) [22]. It also has been shown to be resistant
to bacterial growth. Carbon nanotubes have an antibacterial mechanism that is dependent on their
physical surface structure. For example, cicada wings, dragonfly wings, and black silicon exhibit
antibacterial properties that fall into this category. Their antibacterial properties are attributed to
a nanopillar array on their surface, which ruptures the cell membrane of bacteria on contact [19].
Carbon nanotubes behave in the same way and could be a material that helps a prosthetic retain its
function by being resistant to cellular attachment to its leaflets. This material is also biocompatible
due to its nonreactivity and it is made of pyrolytic carbon, which has been shown to be biocompatible [20,21]. Researchers at BYU tested CI-CNTs to determine its potential for thrombus formation
compared to steel. They performed three experiments, in which the blood of three different people
were flowed past steel and four samples of CI-CNT. One of the CI-CNT samples had no treatment,
while the surfaces of the other three samples were modified. One of the samples had thermal oxidation, the other was manually polished, and the last had an oxygen plasma etch. The results of
the study demonstrated that CI-CNTs with no surface treatment had almost no thrombus formation
when compared to the rest of the samples (See Fig. 3.1).

3.2

Prosthetic Venous Valve Designs
The design for the prosthetic venous valve is based on the constraints of the common

femoral vein. This was chosen because the majority of the cases of LSV reflux occurs in the
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Figure 3.1: Blood compatibility tests performed by researchers at Brigham Young University to
compare the thrombus formation of several CI-CNT samples with that of steel. The y-axis represents the amount of blood that clotted on the sample. The light blue bar represents steel, the orange
bar is the untreated CI-CNT sample, the silver bar is the thermal oxidation modification, the yellow
bar represents the CI-CNT that was manually polished, and the dark blue bar is the plasma etched
CI-CNT.

above knee segment of the leg [34]. It will also be useful to compare this valve with previous
prosthetics that were designed for implantation in the common femoral vein [5, 8, 9]. The common
femoral vein has an average diameter of 12 mm [75].

3.2.1

Design Environment
The geometric designing of the valve was done in Siemens NX 10.0. The NX files were

then uploaded to ANSYS for structural analysis. Only half of the valve was modeled due to
symmetry and to decrease the computational time in the structural analysis. The venous valve
shape was modeled as a thin sheet in NX. The element used in ANSYS was SHELL181, which best
represented the valve since its thickness was very small compared to its length. The thickness of the
valve was specified in ANSYS. An experiment by Fazio determined the relationship between the
infiltration time used to manufacture CI-CNTs and the resulting modulus of elasticity and ultimate
strength. The results showed that when 7 nm of iron was used for growth and the sample was
infiltrated for 120 mins that the modulus of elasticity and ultimate strength were approximately
10 GPa and 153 MPa, respectively [76]. In the stuctural analysis the modulus of elasticity was
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specified as 10 GPa and poisson’s ratio as 0.29. The valve was then meshed in ANSYS using 30
element divisions for each line of the model. Displacement constraints were set on the model so
that the valve walls did not move. This was done since the valve would not move up or down
the vein after implantation. Finally a pressure was applied to the leaflets of the valve, which
represented the hydrostatic or dynamic pressure of blood in the body, depending on whether the
model was being tested for opening or closing. The ANSYS script used for the final design can be
found in Appendix A.

3.2.2

First Design
The first design of the prosthetic venous valve had an outer diameter, valve length, and

leaflet length of 12 mm. The valve was designed to be initially closed. The leaflet linearly transitioned from the connection of the valve to the midpoint of the center of the vein (See Fig. 3.2). A
vertical slit 180 degrees apart from each other was applied to the leaflets to facilitate deflection and
sealing. 5 mmHg was imposed on the leaflets to simulate physiological opening pressures. Upon
structural analysis, the leaflets deflected only 0.013 mm. The maximum stress was 1.81 MPa (See
Fig. 3.3). The curvature and stiffness of the leaflets proved to be unsatisfactory for valve opening.

Figure 3.2: Deflection of first prosthetic venous valve design. The deflection units are in mm.
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Figure 3.3: Stress analysis of first prosthetic venous valve deign. The stress units are in MPa.

The valve design was altered by decreasing the thickness to 70 nm. This resulted in larger
deflections, with a maximum deflection of 0.16 mm (See Fig. 3.4). Even with this small thickness
the valve barely opened with physiological pressures.

Figure 3.4: Deflection of the first design with a wall thickness of 70 nm.

Another alteration was made in the first conceptual design by making horizontal slits
through the leaflets. It was hypothesized that this would decrease the stiffness of the valve leaflets
and allow them to deflect a greater amount. The leaflets were able to bend more than 3 times as
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far as the previous design (See Fig. 3.5). Even with the alteration the leaflets were opening only
approximately 15% of the required deflection that the native valve undergoes to open to 35% of
the vein lumen area.

Figure 3.5: Deflection of the first design with horizontal slits and a thickness of 70 nm.

3.2.3

Second Design
For the second design, the valve was made naturally open with a shorter valve base and

longer leaflets (See Fig. 3.6). This was done to increase the deflection of the leaflets. The valve base
was approximately 6 mm long, with 18 mm leaflets. The leaflets width was linearly transitioned to
a shorter length at the tip in order to seal with the other leaflet without contacting the vein walls. A
hydrostatic pressure of 20 mmHg was applied to the leaflets to test for valve closure. The structural
analysis resulted in a deflection of 0.96 mm. This showed that designing with the valve naturally
open and with longer leaflets helped in decreasing the leaflet’s stiffness and increasing deflection,
but the maximum deflection was still not sufficient for valve closure.

3.2.4

Third Design
In this design, the valve base and leaflet length were 12 mm. The prosthetic was designed

to be naturally open, but unlike previous designs the leaflets initially had the same curvature as the
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Figure 3.6: Deflection of the second design with a hydrostatic pressure of 20 mmHg.

valve base (See Figs. 3.7 and 3.8). This was done after considering the manufacturing of the valve.
It would be ideal to design a valve whose opening geometry would be 35% of the vein lumen
area, but current carbon nanotube growing techniques are limited to flat and cylindrical shapes.
The connection segment between the leaflet and valve was reduced from connecting with its entire
outer edge to connecting to only 1.47 mm of it. This was done to allow for greater deflection and
full leaflet closure. The leaflet was changed to be parabolic in shape to agree with a native valve’s
geometry [8].
The structural analysis of the design yielded a max deflection of 5.57 mm, which is almost
to the midpoint of the vein (See Fig. 3.7). The maximum stress on the valve was 596 MPa (See
Fig. 3.8). Even though the deflection of this design was close to being ideal for valve closure, the
design was infeasible since the maximum stress was greater than the ultimate strength of CI-CNTs.
This design was changed by increasing the width of the connection segment of the valve
and leaflets to 2.72 mm, and lengthening the segment to 2 mm. The thickness of the valve walls
and length of the leaflets were also changed to 0.2 and 18 mm, respectively. The segment and
leaflet length were increased to increase deflection. The segment width and valve thickness were
increased to lower the von Mises stress.
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Figure 3.7: Deflection of the third design with a hydrostatic pressure of 20 mmHg.

Figure 3.8: Stress results of the third design with a hydrostatic pressure of 20 mmHg. Stress units
kg
are mm−s
2.
The changes in the design resulted in an increase of maximum leaflet deflection to 5.69
mm (See Fig. 3.9). The maximum von Mises stress was reduced to 371 MPa (See Fig. 3.10)). This
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Figure 3.9: Deflection results for the third design with a connection segment width and length of
2.72 mm and 2 mm, respectively.

Figure 3.10: Stress results for the third design with a connection segment width and length of 2.72
kg
mm and 2 mm, respectively. Stress units are mm−s
2.
marked an improvement from the previous design, but the maximum stress was still over twice as
high as the ultimate strength of CI-CNTs. The deflection didn’t reach the midpoint of the vein for
complete closure.
It was noted that the maximum von Mises stress occurred at the transition of the straight
connection segment to the rounded leaflet. To decrease the stresses further the transition was made
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smooth. This change resulted in a slight decrease in leaflet deflection to 5.64 mm (See Fig. 3.11),
but the maximum stress was reduced to 305 MPa (See Fig. 3.12).

Figure 3.11: Deflection results for the third design with a smoothed transition between the valve
and leaflet.

To reduce the stress further the length of the connection segment of the valve was increased
even further to 5 mm. The length from the leaflet tip to its connecting point at the base of the
valve was 24 mm. The valve thickness was increased to 0.28 mm to reduce stresses further. This
conceptual design produced a deflection of 5.83 mm and a maximum von Mises stress of 189 MPa
(See Figs. 3.13 and 3.14).

3.2.5

Final Design
For the final design, the valve manufacturing and hemodynamics was taken into consid-

eration. Carbon nanotubes are primarily grown on flat surfaces, with some experimental studies
done on cylindrical surfaces made of stainless steel. To make growth and manufacturing easier the
device should be made on a cylindrical steel rod. The diameter of the prosthetic venous valve was
changed to 12.7 mm, since the closest steel rod dimensions to the common femoral vein is a 0.5
inch diameter rod. The improvements on the initial third design allowed the prosthetic to deflect
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Figure 3.12: Stress results for the third design with a smoothed transition between the valve and
kg
leaflet. Stress units are mm−s
2.
closer to the middle of the vein with less stress, but it also decreased the surface area of the leaflets.
This design would have a large amount of open space that blood could flow through, which could
cause higher reflux rates. To counteract this, flaps were inserted in the design to decrease the
amount of open space that blood might pass through (See Fig. 3.17). The design was optimized to
allow the valve to fully close with a hydrostatic pressure of 20 mmHg, with stresses lower than the
material’s ultimate strength. This objective was achieved by decreasing the connection segment
width to 2.22 mm, and increasing the segment length to 8 mm. The leaflet length was 20 mm. The
valve thickness was changed to 0.27 mm. The CI-CNT prosthetic venous valve produced a deflection of 6.85 mm and had a maximum von Mises stress of 117.17 MPa (See Figs. 3.15 and 3.16).
6.85 mm of deflection allows the leaflets to move just past the midpoint of the vein and completely
seal. The deflection is possible since the maximum von Mises stress is below the ultimate strength
of CI-CNTs.

3.3

Model Reliability
In the real world the mechanical properties of materials can vary greatly even if the material

samples are manufactured with the same conditions and tolerances. This is especially true for the
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Figure 3.13: Deflection results for the third design with a lengthened connection segment.

Figure 3.14: Stress results for the third design with a lengthened connection segment. Stress units
kg
are mm−s
2.
manufacturing of CI-CNTs since the creation process is complex. The manufacturing of CI-CNTs
involves depositing several thin films on the surface of the substrate and growing the nanotubes in a
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Figure 3.15: Deflection results for the final design.

Figure 3.16: Stress results for the final design. Stress units are

kg
.
mm−s2

furnace with flowing gases. This multi step process can result in different mechanical properties of
the CI-CNTs if the film thicknesses, time in the furnace, or flow of the gases are different between
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Figure 3.17: Full CI-CNT prosthetic venous valve model. Top image is a front view of the implant,
middle image is an oblique view, and bottom image is a top view.

production runs. It is essential to design for the mechanical variability of CI-CNTs to ensure the
venous valve will function properly despite differences between each manufactured sample.
To test for this scenario the final design was analyzed subsequently with a 20% reduction
and a 20% increase in the material’s Young’s modulus. The deflection decreased to 5.66 mm as
the Young’s modulus was increased (See Fig. 3.18). This change in turn reduced the maximum
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stress to 114.9 MPa (See Fig. 3.19). On the other hand, decreasing the modulus by 20% caused
the deflection to increase to 8.67 mm and the maximum stress to increase to 120.69 MPa (See
Figs. 3.20 and 3.21). This reliability study shows that there is no danger of the prosthetic failing
under a variable modulus, but the concern regards the proper sealing of the valve leaflets.

Figure 3.18: Deflection results for the final design with a 20% increase in Young’s modulus.

3.4

Model Validation
Validation of the FEA results is important to ensure that the computer simulation correctly

modeled the closing of the valve. It is best to validate computational results by determining a
theoretical solution to a similar problem. The analytical and numerical results can then be compared to ensure model accuracy. This was done to validate the closing of the venous valve by
developing a simple compliant mechanism model. The final prosthetic design was simplified to a
2D pseudo-rigid-body model. This model has been shown to be accurate for bodies that undergo
large, non-linear deflections [77]. The 2D design consisted of a small flexural pivot and a longer
rigid segment (See Fig. 3.22). The thin connection segment in the final design was modeled as the
small flexural pivot. The rigid portion represented the valve leaflet. The deflection induced by the
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Figure 3.19: Stress results for the final design with a 20% increase in Young’s Modulus.

Figure 3.20: Deflection results for the final design with a 20% decrease in Young’s Modulus.

thin connection segment of the final design was modeled as a pin joint with a torsional spring (See
Fig. 3.22). The small flexural pivot had a length of 8 mm and the rigid segment was 12 mm long.
The widths of the small flexural pivot and rigid segment were 2.22 mm and 12 mm, respectively.
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Figure 3.21: Stress results for the final design with a 20% decrease in Young’s Modulus.

The resultant deflection and maximum stress were calculated by imposing a 20 mmHg pressure on
the rigid segment. To determine the deflection, the torque created from the torsional spring was
equated to the moment caused by the pressure applied to the rigid segment (See Eq. (3.1)).

Kθ = Fp (l/2 + L/2) cos θ

(3.1)

In Eq. (3.1), K represents the stiffness of the torsional spring, θ is the angle of deflection,
Fp is the force applied to the rigid segment due to the pressure, l is the length of the small flexural
pivot, and L is the length of the rigid segment. The 20 mmHg hydrostatic pressure caused the rigid
segment to deflect to an angle of 38.06°, which corresponds to a deflection of 9.86 mm.
The maximum stress was calculated by using the moment created by the applied pressure
and the second moment of inertia of the small flexural pivot (See Eq. (3.2)). In Eq. (3.2), I represents the second moment of inertia of the small flexural pivot, and c is the distance to the neutral
axis of the venous valve. The maximum stress that occurred was 142.35 MPa.
The theoretical model resulted in a deflection that was 44% greater than the FEA results.
This deflection caused the maximum stress to increase by 22%. The increased deflection of the
theoretical model is due to the fact that the model is 2D and the second moment of inertia is higher
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Figure 3.22: The pseudo-rigid-body model used to validate the FEA results. The small flexural
pivot is the segment before the torsional spring. The segment to the right of the torsional spring
represents the rigid part of the model (Image from [10]).

for the 3D model, which has a curved cross sectional area. The higher second moment of inertia
in the 3D model increases the stiffness of the leaflets and thus causes less deflection. Even with
these differences the pseudo-rigid-body model proves that the FEA results are realistic since the
deflection and maximum stress values are near the theoretical solution.

σmax =

Fp (L/2 + l/2)c
I
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(3.2)

CHAPTER 4.

4.1

COMPUTATIONAL FLUID DYNAMICS ANALYSIS

Model Creation
A computational analysis was performed on the prosthetic venous valve design to assess the

hemodynamic changes it could create after implantation. The fluent solver in ANSYS workbench
18.2 was used for the analysis. First the valve design was modeled in AutoCAD 2018 and then
uploaded into the Fluid Flow (Fluent) module in the ANSYS workbench. Since the valve was
symmetrical on both sides, only one fourth of the valve was used for the fluid model to reduce the
computational time to solve the simulation. The fluid domain was created by filling in the center
of the vein with a solid and extracting the solid prosthetic venous valve design. 60 mm of the
vein was included after the outlet of the valve to aid in visualizing how the valve would influence
exiting flow dynamics. The prosthetic valve was modeled in the open position to determine the
maximum velocity and shear rates in the vein. The vein was modeled as 12.7 mm in diameter and
100 mm long.

4.2

Initial conditions
Before the simulation was performed the initial inlet flow condition was obtained. The inlet

conditions depend on the material characteristics of blood and the dynamics it has at the inlet of the
prosthetic valve. In a worst case scenario the highest shear rates would be caused by an inlet flow
profile that would drastically change near the vein wall. This scenario would be very similar to a
fully developed profile. The peak flow rate in the femoral vein can be up to 1600 mL/min [61, 75].
To determine the distance the flow needs to travel before it becomes fully developed the Reynolds
number and viscosity of blood need to be obtained. For newtonian fluids the viscosity is a linear
relationship between the shear stress and shear rate (See Eq. (4.1)).
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τrz = µ

∂ vz
∂r

(4.1)

Blood can act like a newtonian and non-newtonian fluid. For shear rates below 50 s−1 , blood acts
like a yield pseudo plastic fluid and the shear stress is not a linear function of the shear rate. At
higher shear rates, above 50 to 80 s−1 , the viscosity of blood is constant and the newtonian equation
correctly models its behavior [78]. In larger vessels, the wall shear rate nearly always exceeds 100
s−1 , and the average shear rate nearly always exceeds 80 s−1 . Since the common femoral vein is
a deep vein it was assumed that the shear rate would be above 80 s−1 and the viscosity of blood
would be constant. The Reynolds number can be calculated by using Eq. (4.2), where ρ, v̄, and
µ represent the density, average velocity, and viscosity of blood, respectively. D represents the
diameter of the vein. The density and viscosity of blood at high shear rates are 1056

kg
m3

and .00345

Pa-s [79].

Re =

ρ v̄D
µ

(4.2)

The average velocity of blood, v̄, can be calculated by using the flow rate through the
common femoral vein (See Eq. (4.3)). In Eq. (4.3), Q represents the flow rate (1600 mL/min),
and A represents the cross section area of the vein (1.27 × 10−4 m2 ). Using Eqs. (4.2) and (4.3)
resulted in an average velocity and Reynolds number of 0.21 m/s and 819.75, respectively.

v̄ =

Q
A

(4.3)

This shows that the flow through the common femoral vein is laminar. When flow is laminar the entrance length, or distance required for fully developed flow, can be calculated by using
Eq. (4.4) [80]. This equated to a entrance length of 521 mm. This inlet condition was captured by
modeling a 12.7 mm vein that was 600 mm long. Only one fourth of the vein was used due to symmetry and to reduce the computational cost of the problem. The velocity at the entrance of the vein
was set at 0.21 m/s and a relative mesh density study was performed until the maximum velocity
changed less than 1%. The fully developed velocity profile at the outlet is shown in Fig. 4.1.

Łentrance = 0.05ReD
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(4.4)

Figure 4.1: Fully developed velocity profile used for inlet condition.

4.3

Meshing
Once the inlet velocity components were saved and the prosthetic venous valve model was

uploaded to ANSYS workbench the fluid domain was meshed. An adaptive medium fine mesh
was used with a growth rate of 1.2. A relative mesh density study was performed to determine
an acceptable mesh for the fluid analysis (See Table 4.1). The element and defeature sizes were
decreased from one test to the next. The defeature size removes small geometric features that are
smaller than the specified size. Since the smallest feature in the model had a size of approximately
0.3 mm, the initial defeature size of the mesh was set at 0.3 mm and the initial element size was 1.5
mm. The maximum velocity of the blood was noted after each test of the mesh study to quantify
a sufficiently fine mesh. The mesh was considered accurate for the simulation once the maximum
velocity of the blood changed less than 1% between the mesh tests. The final mesh size had an
element size of 0.375 mm, a defeature size of 0.075 mm, 38,093 nodes, and 181,312 elements.
The final mesh is shown in Fig. 4.2.

4.4

Solution Setup
The solution was setup and solved using the fluent module in ANSYS workbench. The

fluid model used was set to laminar flow, with the viscosity and density of blood. The inlet was set
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Table 4.1: Prosthetic Mesh Study
Mesh Density
1
2
3
4

Element Size (mm)
1.5
0.75
0.5
0.375

Defeature Size (mm)
0.3
0.15
0.1
0.075

Maximum Velocity (m/s)
.38063
.38978
.39588
.39591

Figure 4.2: Mesh of fluid domain.

to a velocity-inlet boundary with the velocity components being the data that was saved from the
fully developed profile. The outlet was a pressure outlet with a gauge pressure of 0 Pa. The wall
of the vein and valve were wall boundaries with the no slip mode enabled. Finally, the faces of
symmetry were set to the symmetry boundary condition.

4.5

CFD Results
The fully developed peak flow rate through the valve resulted in an increase of the maxi-

mum velocity from 0.379 m/s to 0.395 m/s at the centerline of the vein (See Fig. 4.3). The velocity
profile throughout the vein was undisturbed with no reversed flow.
The maximum shear rate in the vein was 225.1 s−1 . This occurred at the inlet of the venous
valve where the inner diameter of the vein decreased due to the valve’s thickness (See Figs. 4.4
to 4.6). There was also a smaller region of high shear rates at the corner of the top flap (See
Fig. 4.7). Although these shear rates are higher relative to the other shear rates throughout the
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Figure 4.3: Velocity profiles at the planes of symmetry.
valve, they are still far below 3500 s−1 . This indicates that the prosthetic venous valve would be
far less likely to form red blood clots due to elevated shear rates.
The minimum shear rate experienced throughout the vein was 0.123 s−1 . This primarily
took place around the borders of the valve leaflets and between the leaflet flaps (See Figs. 4.7
and 4.9). The lowest shear rates occurred near the top and bottom of the leaflet flaps, which had
smaller open areas for blood to pass through. Opening and closing of the valve will help increase
the shear rates in these regions. Overall, the average shear rates in the areas around the borders
of the leaflets and leaflet flaps were approximately 65 s−1 . Since the average shear rates in these
areas is above 46 s−1 , thrombosis formation would likely not occur, but further testing needs to be
done to determine if blood will coagulate in these regions.
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Figure 4.4: Shear rate throughout the vein.

4.6

Model Validation
To ensure that the CFD shear rate results were correct and in the appropriate range a theo-

retical wall shear rate in the common femoral vein was calulated. Assuming the blood in the vein is
a newtonian fluid, the flow is steady and laminar, and the vein is straight and inelastic, Poiseuille’s
law may be applied to determine the wall shear rate (See Eq. (4.5)) [81]. In Eq. (4.5), Q is the flow
rate through the vein, d is vein diameter, and γ̇ represents the wall shear rate. Using the peak flow
experienced in the femoral vein, 1600 mL/min, and a vein diameter of 12.7 mm, the wall shear
rate would be 132.6 s−1 . This shows that in a common femoral vein without any obstructions or
venous valve the wall shear rate would be close to 132.6 s−1 . The theoretical shear rate validates
the CFD shear rate since the CFD result is slightly above the theoretical value. This slight increase
is to be expected due to the inclusion of the prosthetic venous valve.

γ̇ =

32Q
πd 3
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(4.5)

Figure 4.5: Shear rate near the prosthetic venous valve

Figure 4.6: Shear rates near the inlet of the valve.
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Figure 4.7: Shear rates through the middle of the valve.

Figure 4.8: Shear rates near the outlet of the valve.
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Figure 4.9: Region of low shear rates.
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CHAPTER 5.

5.1

DISCUSSION AND CONCLUSIONS

Discussion
The purpose of this research was to design an effective prosthetic venous valve that would

help treat the source of the problem of CVI. There are many treatments for CVI that treat the symptoms of the disease but very few have been effective in restoring the function of the venous valve in
the long-term for secondary venous incompetence. Over the last few decades many attempts have
been made to design a prosthetic venous valve that could restore the function of the native valve
and reverse the symptoms of the disease. The major problems that have stopped the clinical use of
the top performing valves are biocompatibility issues, high shear rates induced by the valves that
lead to blood clots, and long term dysfunction of the valve caused by neointimal hyperplasia of the
valve’s leaflets.
The prosthetic venous valve of this research was designed to overcome these issues by using
a material that is biocompatible, thrombo-resistant, and has the possibility of reducing neointimal
hyperplasia. It was also designed to have physiological shear rates and function like the native
venous valve by closing at physiological pressures. These parameters were accomplished and
verified by FEA and CFD analysis. The valve successfully closed at a pressure of 20 mmHg with
the maximum stress being over 23% below the ultimate strength of CI-CNTs. The maximum shear
rate was far below the maximum physiogical shear rate of 3500 s−1 , above which coagulation can
occur. Although the average shear rate in the low shear rate regions was 65 s−1 , the minimum
shear rate in the valve was below the physiological minimum of 46 s−1 . It is anticipated that
shear rates in these regions will increase by the opening and closing of the valve leaflets, but
further testing is required to determine if thrombus formation will occur. When compared to other
prosthetics this venous valve has the lowest shear rates during forward flow. The shear rates of
recent top performing valves are 2,300 s−1 for Tanner’s device, 7,600 s−1 for Akron’s second
generation valve, over 10,000 s−1 for Sathe’s prosthetic, and 3,000 s−1 for Midha’s venous valve.
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Implantation of a CI-CNT venous valve would increase the wall shear rates by 70% compared to
the normal wall shear rates. In comparison, previous prosthetic venous valves would increase the
normal wall shear rates anywhere from 746 to 3,582%. This shows the great impact the CI-CNT
valve can make in minimizing wall shear rates and reducing the potential of blood clot formation.
This will ensure that the hemodynamics in the vein are no perturbed and the prosthetic functions
without damage from coagulation.
There are also several limitations and challenges associated with the design. The final
design has slits that were made to allow the leaflets to deflect to the closed position. These slits
may allow small amounts of blood to reflux toward the lower extremities. Even in healthy veins
a small amount of reflux is normal. As long as the reflux rate is below pathological values the
valve will perform well, but testing should be done to assure this feature does not decrease the
efficacy of the valve. The reliability test that was done to ensure proper leaflet operation with a
variable Young’s modulus is also an area of concern. If the manufacturing of the valve were to
have variability that decreased the materials modulus by 20%, then the leaflets would still properly
close and the maximum stress experienced would be below the ultimate strength of CI-CNTs. On
the other hand, if there were cases where the modulus increased by 20%, the leaflets might not
completely seal. This could lead to pathologic reflux to the lower extremities, which would cause
increased hypertension and disease progression. Further studies must be done in the manufacturing
of the CI-CNT valves to determine the range of mechanical properties that these prosthetics will
have and if it will cause a problem with valve function. Another limitation in this design is the
long term life of the implant. A fatigue analysis was not performed to determine the amount of
time the CI-CNT valve would last in the human body. The fatigue life was not determined for the
CI-CNT prosthetic because very few tests have been performed to determine the fatigue strength or
marin correction factors for carbon nanotubes. Without this data the calculated fatigue life would
be inaccurate. Further testing and experimentation need to take place to determine the fatigue life
of CI-CNTs.

5.2

Contributions
This thesis contributes the first conceptual CI-CNT prosthetic venous valve design to date.

The major areas of contributions are: the design and optimization of a naturally open prosthetic
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venous valve that closes with the minimum required pressure in the common femoral vein, and
testing of the design in a structural and fluid environment to assess its functional capabilities and
impact after implantation.

5.3

Recommendations
To further the progress of this CI-CNT venous valve future work needs to be done. The

actual manufacturing of the valve needs to take place along with its testing. The manufacturing of
the valve will require the growth of carbon nanotubes. Carbon nanotube growth would be optimal
on a stainless steel rod due to the fact that the valve will be cylindrical and previous studies have
shown success with growth on similar surfaces [82]. This process entails depositing 80 nm of
alumina on the substrate, followed by 7 nm of iron with a mask applied to the surface of the rod
to ensure growth of the carbon nanotubes in the shape of the venous valve. The carbon nanotubes
will then be grown by placing the rod in a furnace at elevated temperatures and flowing hydrogen
and ethylene in the proper process to achieve the desired CI-CNT height [82]. The CI-CNT venous
valve will then need to be detached from the steel rod by an etching process. Growing the carbon
nanotubes on a quartz rod is another possibility that could facilitate the venous valve detachment.
In order for the valve to advance to clinical use it needs to be tested to verify that it can
perform all the functions of a native venous valve. It must open and close under the right conditions
with minimal reflux and the added outflow resistance due to implantation must be lower than
pathological values. Long term competency and patency is essential to have a valve that can be
a long term solution for CVI, without clotting or failing through leaflet thickening. To verify that
the valve can replace a dysfunctional venous valve for the long term a test should be performed by
placing the valve in a pulsatile flow loop for fatigue testing with physiologic pressures. A separate
blood flow loop test would be helpful to experimentally prove the valve’s resistance to thrombus
formation. To quantify the outflow resistance and reflux flow rates, tests should be performed
by controlling the pressure and measuring the flow rate and leak rate. Through these tests the
performance of the CI-CNT valve can be quantified and prosthetic venous valve implantation can
become a reality.
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[68] I. Höjensgard, “Static and dynamic pressures in superficial and deep veins of the lower extremity in man,” Acta Physiologica Scandinavica, vol. 27, pp. 49–67, 1953. 25
[69] C. Stick, U. Hiedl, and E. Witzleb, “Venous pressure in the saphenous vein near the ankle
during chanes in posture and exercise at different ambient temperatures,” European journal
of applied physiology and occupational physiology, vol. 66, pp. 434–438, 1993. 25
62

[70] Y. Alimi, P. Barthelemy, and C. Juhan, “Venous pump of the calf: a study of venous and
muscular pressures,” Journal of Vascular Surgery, vol. 20, pp. 728–735, 1994. 25
[71] M. A. Vasquez, J. Wang, M. Mahathanaruk, G. Buczkowski, E. Sprehe, and H. H. Dosluoglu, “The utility of the venous clincal severit score in 682 limbs treated by radiofrequency
saphenous vein ablation,” Journal of Vascular Surgery, vol. 45, pp. 1008–1014, 2007. 28
[72] R. M. Barstad, H. E. Roald, Y. Cui, V. T. Turitto, and K. S. Sakariassen, “A perfusion chamber
developed to investigate thrombus formation and shear profiles in flowing native human blood
at the apex of well-defined stenoses,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 14, pp. 1984–1991, 1994. 28
[73] R. Barstad, P. Kierulf, and K. Sakariassen, “Collagen induced thrombus formation at the apex
of eccentric stenoses: a time course study with non-anticoagulated human blood,” Thrombosis
and haemostasis, vol. 75, pp. 685–692, 1996. 28
[74] A. Para, D. Bark, A. Lin, and D. Ku, “Rapid platelet accumulation leading to thrombotic
occlusion,” Annals of biomedical engineering, vol. 39, pp. 1961–1971, 2011. 28
[75] A. e. a. Fronek, “Common femoral vein dimensions and hemodynamics including valsalva
response as a function of sex, age, and ethnicity in a population study,” Journal of Vascular
Surgery, vol. 33, pp. 1050–1056, 2001. 30, 46
[76] W. C. Fazio, “Mechanical properties and mems applications of carbon-infiltrated carbon nanotube forests,” Master’s thesis, Brigham Young University. 30
[77] L. L. Howell, Compliant Mechanisms.
Sons, Inc., 2001. 42

605 Third Avenue, New York, NY: John Wiley &

[78] E. W. Merrill and G. A. Pelletier, “Viscosity of human blood: transition from newtonian to
non-newtonian,” Journal of Applied Physiology, vol. 23, pp. 178–182, 1967. 47
[79] S. Madihally, Principles of Biomedical Engineering.
Artech House, 2010. 47

685 Canton Street, Norwood, MA:

[80] T. L. Bergman, A. S. Lavine, F. P. Incropera, and D. P. DeWitt, Fundametnals of heat and
mass transfer. Hoboken, NJ: Wiley, 2011. 47
[81] T. G. Papaioannou and C. Stefanadis, “Vascular wall shear stress: Basic principles and methods,” Hellenic Journal of Cardiology, vol. 46, pp. 9–15, 2005. 51
[82] R. Warren, B. Jensen, and A. Bowden, “Patterned carbon nanotube growth on conve cylindrical stainless steel substrates for the producion of coronary stents,” in Proceedings of ASME
International Design Engineering Technical Conferences and Computers and Information in
Engineering Conferences IDETC2016, vol. 4: 21st Design for Manufacturing and the Life
Cycle Conference; 10th International Conference on Micro- and Nanosystems, Aug. 2016.
57

63

APPENDIX A.

ANSYS SCRIPT FILE FOR FINAL DESIGN

FINISH !Exits whatever processor ANSYS is in
/CLEAR !Clears the existing analysis
/FILNAME,venousvalve ellipse,0 !Changes the JobName
/CWD,’C:\Users\rcpacker\Documents’
!Changes the working directory of the local drive.
KEYW, PR SET, 1
KEYW, PR STRUC, 1
FINISH /BEGIN
!Parameters
!Geometry
!Thickness
t = .3
!Material properties
E = 1e7
!poissons ratio
nu = .29
!meshing parameters
elementdiv = 30
!Load in nx file
˜UGIN,’basic design test2 circum2 22 r 3 taper length 8 chamfer leaflet 20 seal both
ends dia12.7 tighter slit short top flap’,’prt’,’J:\Graduate Research\compliant hinge
designs\segment 2 72\24mm leaflet’,ALL,1-256,0
FINISH
/PREP7 !Enter preprocessor environment
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!Define Material Model
MPTEMP,,,,,,,,
MPTEMP,1,0
MPDATA,EX,1,,E
MPDATA,PRXY,1,,nu
!Define Element Type
ET,1,SHELL181
!Define shell thickness
sect,1,shell,,
secdata,t,1,0.0,3
secoffset,TOP
seccontrol,0,0,0,0,1,1,1
!mesh
ESIZE,0,elementdiv,
MSHAPE,0,2D
MSHKEY,0
AMESH,all
ALLSEL
!Finish by manually setting displacement constraints and pressures
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